Does fish oil protect the heart? Decoding the omega-3 claim

Fish oil is one of the most widely purchased supplements on the market, largely on the strength of the claim that omega-3 fatty acids protect the heart. Four large, independently run randomized trials have tested versions of this claim directly, and they do not all agree, which makes omega-3 a genuinely mixed case rather than a simple yes or no.

What the general-population trials found

The largest and most directly relevant trial for a healthy general population is the omega-3 arm of VITAL (Manson and colleagues, New England Journal of Medicine, 2019), which randomized 25,871 US adults, men 50 and older and women 55 and older with no prior cardiovascular disease, to 1 gram of marine omega-3 fatty acids daily or placebo for a median of 5.3 years. The primary result was null: no significant reduction in the composite of heart attack, stroke, and cardiovascular death (hazard ratio 0.92, 95% CI 0.80 to 1.06) and no reduction in total invasive cancer. A secondary analysis of heart attack alone did show a reduction (hazard ratio 0.72, 95% CI 0.59 to 0.90), but that was one component of a larger composite that did not reach significance, so it should be read as a signal worth further study rather than a confirmed, standalone benefit.

The ASCEND trial (Bowman and colleagues, New England Journal of Medicine, 2018) tested the same basic question in 15,480 adults with diabetes but no known cardiovascular disease, randomized to 1 gram of omega-3 fatty acids (EPA and DHA) daily or an olive oil placebo. The result was again null: no significant difference in the rate of serious vascular events, the trial’s primary outcome, between the omega-3 group and placebo.

The STRENGTH trial (Nicholls and colleagues, JAMA, 2020) tested a much higher dose, 4 grams a day of a combined EPA/DHA carboxylic acid formulation, against corn oil in 13,078 statin-treated patients at high cardiovascular risk with elevated triglycerides and low HDL. It found no significant difference in major adverse cardiovascular events between the omega-3 group and corn oil (hazard ratio 0.99) and was stopped early for futility. It also found a significantly higher rate of atrial fibrillation in the omega-3 group. Between VITAL, ASCEND, and STRENGTH, three large, independent, general-population or high-risk trials using standard fish-oil-type doses all reported null primary cardiovascular results.

The one positive trial, and why it is contested

REDUCE-IT (Bhatt and colleagues, New England Journal of Medicine, 2019) is the exception, and it is the trial most often cited in support of the fish-oil-protects-the-heart claim. It tested a much higher dose than a typical fish oil supplement, 4 grams a day of icosapent ethyl, a purified and stabilized form of EPA alone, in 8,179 statin-treated patients with elevated triglycerides and either established cardiovascular disease or diabetes with risk factors. The result was a substantial 25% relative risk reduction in the composite primary endpoint (17.2% versus 22.0%; hazard ratio 0.75, 95% CI 0.68 to 0.83), a large and statistically strong effect.

The complication is the placebo. REDUCE-IT used mineral oil as its comparator, and mineral oil is known to raise LDL cholesterol and some inflammatory markers, which means part of the apparent benefit of icosapent ethyl could reflect the placebo group looking worse rather than the treatment group looking better. This is not a fringe objection; it has been argued in the cardiology literature in both directions. Bostrom, Beckman, and Berger (Circulation, 2021) raised it directly, comparing REDUCE-IT’s positive result against STRENGTH’s null result with a non-mineral-oil comparator as a reason for caution. The trial’s own investigators and other analyses have pushed back that the biomarker shifts seen with mineral oil are too small to explain a 25% relative risk reduction. The honest position is that this is a live, unresolved dispute among specialists rather than a settled question, and REDUCE-IT remains the single largest positive cardiovascular trial for any omega-3 product, tested at a prescription dose and formulation that is not what most over-the-counter fish oil supplements deliver.

Where a general fish oil bottle fits, and where it does not

The distinction that gets lost in the marketing is dose and formulation. VITAL, ASCEND, and the null result in STRENGTH all tested doses and mixed EPA/DHA formulations closer to what is sold as an over-the-counter fish oil supplement, roughly 1 to 4 grams a day of combined EPA and DHA, and none of them found a general cardiovascular benefit in the populations studied. REDUCE-IT’s positive result came from a single, purified, high-dose EPA-only prescription product tested in people who already had elevated triglycerides and either existing cardiovascular disease or diabetes with additional risk factors, not a healthy general population taking a supplement off the shelf. Whether a specific triglyceride level or existing cardiovascular risk profile puts someone in the population REDUCE-IT actually studied is a clinical determination that depends on lab values and history, not something a supplement label can establish.

The honest bottom line

Three of the four large randomized trials on omega-3 fatty acids and cardiovascular outcomes, run in generally healthy adults, people with diabetes, and high-risk statin-treated patients, found no significant reduction in cardiovascular events from standard fish-oil-type doses. The fourth, REDUCE-IT, found a large benefit, but at a prescription dose and formulation most supplement users are not taking, and using a placebo comparator whose own cardiovascular neutrality is genuinely disputed among researchers. That combination, real evidence on one specific product and population alongside repeated null results everywhere else, is why the broad claim that fish oil protects the heart lands as mixed rather than clearly supported.